BRCA1 and breast cancer: 60-, 120-, and 150-month breast cancer-specific survival (BCSS) had no significant difference, but poorer BCSS was observed in the non-carrier group (91.4%, 88.8%, and 88.8% for BRCA1/2 carriers vs. 87.4%, 82.4%, and 82.4% for non-carriers P = 0.1571, 0.0724, and 0.0724, respectively).